Clinical Research Directory
Browse clinical research sites, groups, and studies.
Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain
Sponsor: Sun Yat-sen University
Summary
To study the 2-year PFS (progression-free survival) of patients with stage II-III nasopharyngeal carcinoma treated with induction chemotherapy followed by two different doses of intensity modulated radiation therapy plus concurrent cisplatin chemotherapy
Official title: Phase III Randomized Non-inferiority Trial of Reduced-dose Versus Standard Dose Radiotherapy for Stage II-III Nasopharyngeal Carcinoma Which Have Favorable Response After Induction Chemotherapy
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
452
Start Date
2022-05-11
Completion Date
2029-10-29
Last Updated
2025-03-21
Healthy Volunteers
No
Conditions
Interventions
IMRT
Patients in experimental group received reduced dose IMRT
induction chemotherapy
cisplatin-based induction chemotherapy for two cycles
cisplatin concurrent chemotherapy
cisplatin 100mg/m2, for two(60Gy) or three cycles(70Gy)
Locations (1)
Sun Yat-sen Universitty Cancer Center
Guangzhou, Guangdong, China